Amwell (NYSE: AMWL) reported Q2 EPS of ($0.33), $0.11 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $62.4 million versus the consensus estimate of $65.86 million.

GUIDANCE:

Amwell sees FY2023 revenue of $257-263 million, versus the consensus of $276.7 million.

For earnings history and earnings-related data on Amwell (AMWL) click here.